VINCENT TAM to Drug Resistance, Bacterial
This is a "connection" page, showing publications VINCENT TAM has written about Drug Resistance, Bacterial.
Connection Strength
4.007
-
Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates. J Glob Antimicrob Resist. 2017 12; 11:154-155.
Score: 0.466
-
An institutional review of antimicrobial stewardship interventions. J Glob Antimicrob Resist. 2016 09; 6:75-77.
Score: 0.420
-
Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother. 2012 Apr; 56(4):1680-5.
Score: 0.312
-
Predicting bacterial fitness cost associated with drug resistance. J Antimicrob Chemother. 2012 Apr; 67(4):928-32.
Score: 0.312
-
Optimizing dosage to prevent emergence of resistance - lessons from in vitro models. Curr Opin Pharmacol. 2011 Oct; 11(5):453-6.
Score: 0.304
-
Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2008 Aug; 52(8):2898-904.
Score: 0.243
-
Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008 Mar 15; 46(6):862-7.
Score: 0.239
-
Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2007 Jul; 58(3):309-14.
Score: 0.228
-
Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis. 2007 Jun 15; 195(12):1818-27.
Score: 0.225
-
The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother. 2007 Feb; 51(2):744-7.
Score: 0.218
-
Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005 Dec; 49(12):4920-7.
Score: 0.204
-
Mathematical modelling of resistance emergence. J Antimicrob Chemother. 2005 Nov; 56(5):983; author reply 983-4.
Score: 0.201
-
Prevalence of extended-spectrum beta-lactamase and carbapenemase-producing bloodstream isolates of Klebsiella pneumoniae in a tertiary care hospital. J Chemother. 2018 Apr; 30(2):115-119.
Score: 0.117
-
Correlation of hospital carbapenem consumption and resistance trends in selected gram-negative bacteria. Ann Pharmacother. 2012 Jul-Aug; 46(7-8):1120-2.
Score: 0.081
-
Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design. J Antimicrob Chemother. 2011 May; 66(5):1079-86.
Score: 0.073
-
Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother. 2010 Mar; 54(3):1173-8.
Score: 0.068
-
Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model. J Antimicrob Chemother. 2009 Sep; 64(3):556-62.
Score: 0.066
-
Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. Antimicrob Agents Chemother. 2008 Nov; 52(11):3987-93.
Score: 0.062
-
Mathematical modelling response of Pseudomonas aeruginosa to meropenem. J Antimicrob Chemother. 2007 Dec; 60(6):1302-9.
Score: 0.058
-
Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2006 Jan; 50(1):310-7.
Score: 0.051
-
Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005 Sep; 49(9):3624-30.
Score: 0.050
-
Rhodococcus equi pneumonia in a patient with human immunodeficiency virus: case report and review. Pharmacotherapy. 2001 Aug; 21(8):998-1002.
Score: 0.009